Health Trials

A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies

ConditionsAcute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, in Relapsed or RefractoryMDS (Myelodysplastic Syndrome)
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorARCE Therapeutics, Inc.

About this trial

This study will evaluate the long-term safety of ARD103 cellular therapies

Eligibility criteria

Qualifiers

The participant has R/R AML or MDS and has previously received ARD103 CAR-T cell therapies in the parent study.

The participant is able to understand and comply with protocol-required study procedures and has provided a written informed consent document.

Disqualifiers

There are no specific exclusion criteria for this study

Trial design

Treatments tested in this trial

  • Non interventional study

Treatment groups

49 Participants
are divided into 1 treatment group

Sponsors and collaborators

ARCE Therapeutics, Inc.

Lead sponsor

Source ClinicalTrials.gov